Augmentation of depressed Lymphokine Activated Killer activity by continuous intravenous-administration of Recombinant Interleukin 2 to patients with Hepatocellular carcinoma

Masanao Fujikawa; Hirosi Sakaeda; Shinichi Iwamura; Yasushi Matuura; Eiji Ido; Youichi Matunaga; Takashi Maeda; Toshiji Saibara; Saburo Onishi; Kenichi Ito

doi:10.2177/jsci.10.201

Masanao Fujikawa, Hirosi Sakaeda, Shinichi Iwamura, Yasushi Matuura, Eiji Ido, Youichi Matunaga, Takashi Maeda, Toshiji Saibara, Saburo Onishi, Kenichi Ito

Author information

Masanao Fujikawa
The First Department of Internal Medicine, Kochi Medical School
Hirosi Sakaeda
The First Department of Internal Medicine, Kochi Medical School
Shinichi Iwamura
The First Department of Internal Medicine, Kochi Medical School
Yasushi Matuura
The First Department of Internal Medicine, Kochi Medical School
Eiji Ido
The First Department of Internal Medicine, Kochi Medical School
Youichi Matunaga
The First Department of Internal Medicine, Kochi Medical School
Takashi Maeda
The First Department of Internal Medicine, Kochi Medical School
Toshiji Saibara
The First Department of Internal Medicine, Kochi Medical School
Saburo Onishi
The First Department of Internal Medicine, Kochi Medical School
Kenichi Ito
The First Department of Internal Medicine, Kochi Medical School

Keywords: α-fetoprotein, hepatocellular carcinoma, lymphokine activated killer cells, Interleukin 2

JOURNAL FREE ACCESS

1987 Volume 10 Issue 2 Pages 201-206

DOI https://doi.org/10.2177/jsci.10.201

Details

Abstract

We pointed previously two problems in treating hepatocellular carcinoma (HCC) with lymphokine activated killer (LAK) cells: one is the difficulty in inducing LAK activity and the other is the existence of serum inhibitory factor in LAK generation. In this paper, 14 HCC patients were injected with recombinant interleukin 2 (rIL-2) 15 μg/day continuously for 5 to 27 days, and were assessed for its immunological influence and clinical effect. Results indicated that LAK activity which was lower estimated before the treatment, was remarkably increased in 9 of 12 patients and more than 25 percent reduction of serum α-fetoprotein (AFP) concentration was observed in 5 to 13 patients. Therefore, it could be suggested that continuous intravenous-administration of rIL-2 seemed possible to overcome a problem in adoptive immunotherapy in HCC.

Corresponding author

Register with J-STAGE for free!